Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants
← catalyst calendarNCT07629999 · readout in 286 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
136estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-13 | actual | When the study began enrolling |
| Primary completion | 2027-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: BMS-986533
- Drug: Famotidine
- Drug: Placebo
- Drug: Dabigatran Etexilate
- Drug: Rosuvastatin
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Adverse Events (AE)
measured Up to Day 47
Number of participants with Serious Adverse Events (SAE)
measured Up to Day 47
Number of participants with Vital Sign Abnormalities
measured Up to Day 27
Number of participants with Physical Examination Abnormalities
measured Up to Day 27
Number of participants with Electrocardiogram (ECG) Abnormalities
measured Up to Day 27
Number of participants with Clinical Laboratory Assessments Abnormalities
measured Up to Day 27
Number of participants with Treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
measured Up to Day 27
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed